Search This Blog

Wednesday, July 17, 2019

FDA accepts Allergan Bimatoprost SR application to lower intraocular pressure

The FDA accepts for review Allergan’s (NYSE:AGN) marketing application for Bimatoprost Sustained-Release (SR) for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The agency’s action will be in late H1 2020.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)